| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Total revenue | 65,324 | |||
| Research and development | 106,740 | |||
| General and administrative | 43,933 | |||
| Total operating expenses | 150,673 | |||
| Loss from operations | -85,349 | |||
| Interest expense | 7,681 | |||
| Interest and investment income, net | 9,442 | |||
| Change in fair value of series 1 nonconvertible preferred stock | 39 | |||
| Total other income, net | 1,800 | |||
| Loss before income taxes | -83,549 | |||
| Income tax benefit (expense) | -1,660 | |||
| Net loss | -81,889 | |||
| Diluted | -3.84 | |||
| Earnings per share, basic | -3.84 | |||
| Weighted average number of shares outstanding, basic | 21,336 | |||
| Weighted average number of shares outstanding, diluted | 21,336 | |||
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)